During the last session, Biocept Inc. (NASDAQ:BIOC)’s traded shares were 1.27 million, with the beta value of the company hitting 0.94. At the end of the trading day, the stock’s price was $2.32, reflecting an intraday loss of -45.41% or -$1.93. The 52-week high for the BIOC share is $47.70, that puts it down -1956.03 from that peak though still a striking -78.88% loss since the share price plummeted to a 52-week low of $4.15. The company’s market capitalization is $1.38M, and the average intraday trading volume over the past 10 days was 0.81 million shares, and the average trade volume was 114.30K shares over the past three months.
Biocept Inc. (BIOC) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 3.00. BIOC has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Biocept Inc. (NASDAQ:BIOC) trade information
Biocept Inc. (BIOC) registered a -45.41% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -45.41% in intraday trading to $2.32 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -57.70%, and it has moved by -71.86% in 30 days. Based on these gigs, the overall price performance for the year is -94.50%. The short interest in Biocept Inc. (NASDAQ:BIOC) is 10260.0 shares and it means that shorts have 3.95 day(s) to cover.
The consensus price target of analysts on Wall Street is $330.00, which implies an increase of 99.3% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $330.00 and $330.00 respectively. As a result, BIOC is trading at a discount of -14124.14% off the target high and -14124.14% off the low.
Biocept Inc. (BIOC) estimates and forecasts
In the rating firms’ projections, revenue will decrease -72.00% compared to the previous financial year.
Revenue for the current quarter is expected to be $1.58 million as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to $1.65 million by the end of Jun 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $19.95 million and $10.61 million respectively. In this case, analysts expect current quarter sales to shrink by -92.10% and then drop by -84.50% in the coming quarter.
While earnings are projected to return -890.30% in 2023, the next five years will return 40.00% per annum.
Biocept Inc. is due to release its next quarterly earnings between May 22 and May 26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Biocept Inc. (NASDAQ:BIOC)’s Major holders
The next largest institutional holding, with 5263.0 shares, is of Blackrock Inc.’s that is approximately 0.03% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $53682.0.